VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question

In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.

• Source: Alamy

US lawmakers are concerned about both the prevalence of adulterated dietary supplements the US marketplace and the lack of additional drugs being made available OTC. One of the problems got targeted funding in the fiscal year 2022 appropriation for federal agencies.

The omnibus FY2022 spending bill provides the Food and Drug Administration with funding targeted for enforcement against adulterated supplements...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation